Mouse Anti-CD7 Recombinant Antibody (clone RFT2) (CAT#: FAMAB-0050CQ)

Figure 1 Increasing amounts (0.05-2 μg/ml) of RFT2 causes increasing inhibition of the T cell response to tuberculin PPD.

The response is shown as a percentage of that in the presence of PPD alone and represents the results of four experiments. NS. not significant; *<0.03; +P< 0.06; ++<0.009.

Costantinides, Y., Kingsley, G., Pitzalis, C., & Panayi, G. S. (1991). Inhibition of lymphocyte proliferation by a monoclonal antibody (RFT2) against CD7. Clinical & Experimental Immunology, 85(1), 164-167.

Figure 2 The effect of RFT2 (0; 0.05; 0.2 and 2.0 μg/ml) Oh the proliferation of T cells from control subjects induced by phylohucmagglulinin (PHA), concanavalin A (ConA) phorbol myristate actate (PMA) and OKT3.

The results from four separate experiments are shown and the bars represent the means. *P

Costantinides, Y., Kingsley, G., Pitzalis, C., & Panayi, G. S. (1991). Inhibition of lymphocyte proliferation by a monoclonal antibody (RFT2) against CD7. Clinical & Experimental Immunology, 85(1), 164-167.

Figure 3 Mononuclear cells (MNC) incubated with RFT2 (a) or an irrelevant monoclonal antibody (b) were washed and added at various number to fresh MNC which were stimulated with PPD.

The results of four experiments are shown. *P<0.03 when compared with cultures containing the same number of MNC both fresh and pre-treated with the irrelevant monoclonal antibody. All other differences are not significant.

Costantinides, Y., Kingsley, G., Pitzalis, C., & Panayi, G. S. (1991). Inhibition of lymphocyte proliferation by a monoclonal antibody (RFT2) against CD7. Clinical & Experimental Immunology, 85(1), 164-167.

Figure 4 The expression of interlcukin-2 receptor (IL-2R) on the surface of T cells stimulated with tuberculin PPD for 2 days or 5 days in the presence or absence of RFT2. The results of three separate experimenis are shown.

Costantinides, Y., Kingsley, G., Pitzalis, C., & Panayi, G. S. (1991). Inhibition of lymphocyte proliferation by a monoclonal antibody (RFT2) against CD7. Clinical & Experimental Immunology, 85(1), 164-167.

Figure 5 Immunohistologic specificity of the binding of RFT2 (A and B) and CHT2 (C and D) on normal thymus(A and C) and tonsil (B and D).

Note the identical reactivity pattern and the simiby both mAb. Arrows point to very larly wide range of staining intensity seen strongly positive T blast cells inslde the thymic cortex. In Band D the broken line delineates the boundary between the follicle with germinal center (gc) and the T cell-rich paracortical region (PC). ascertained by double staining for IgM deposits in the germinal center (not shown). Apart from T lineage cells no other cell types In the body are labeled with CHTP.

Heinrich, G., Gram, H., Kocher, H. P., Schreier, M. H., Ryffel, B., Akbar, A., ... & Janossy, G. (1989). Characterization of a human T cell-specific chimeric antibody (CD7) with human constant and mouse variable regions. The Journal of Immunology, 143(11), 3589-3597.

Figure 6 Triple immunofluorescent analysis of RFTP (E and D) and CHT2, reactivity(C and E) of blood lymphocytes expressing CD45 R (LCA, p220.200: A, B, and C) and UCHLl (LCA. p180: A. D, and E).

The lymphocyte populations were gated on the forward angle and side scatterby using a FACScan flow cytometer. The three immunofluroescent channels included DuoCHROME (DC; UCHL1-biotin with streptavidin second layer) phycoerythrin (PE; directly labeled CD45R) and FITC. The latter was either used directly (RFT2-FITC) or indirectly (CHT2 with goat antihuman-Ig-FITC). The B lymphocyte populations (strongly CD45R+. but UCHLI- RFT2-) shown in boxes represent 7.0% of lymphocytes counted.

Heinrich, G., Gram, H., Kocher, H. P., Schreier, M. H., Ryffel, B., Akbar, A., ... & Janossy, G. (1989). Characterization of a human T cell-specific chimeric antibody (CD7) with human constant and mouse variable regions. The Journal of Immunology, 143(11), 3589-3597.

Figure 7 CD7 expression detected by RFTP (a) and CHTP (b) on T lymphoid populations.

(A) unstimulated UCHLl+ T lymphocytes; (B) unstimulated CD45R+ T cells; (C) T-ALL blast cells; (D) lymphoblasts from 64-h PHA stimulated cultures. Note that "A" include CD7- and CD7± cells, "B" include CD7+ cells, whereas both T-ALL blasts and T lymphoblasts show even stronger positivity. RFTP was conjugated to FITC and CHTPbiotin was detected with streptavidin-FITC

Heinrich, G., Gram, H., Kocher, H. P., Schreier, M. H., Ryffel, B., Akbar, A., ... & Janossy, G. (1989). Characterization of a human T cell-specific chimeric antibody (CD7) with human constant and mouse variable regions. The Journal of Immunology, 143(11), 3589-3597.

Figure 8 ADCC using CF⁵¹-labeled T-ALL (a and b, two cases) or PHA blasts (c).

Effector cells were PBMC from healthy donors. Target cells were coated with CHTP, RFTZ or uncoated by using a control irrelevant mAb at 1 μg/ml 10⁸ cells /ml.

Heinrich, G., Gram, H., Kocher, H. P., Schreier, M. H., Ryffel, B., Akbar, A., ... & Janossy, G. (1989). Characterization of a human T cell-specific chimeric antibody (CD7) with human constant and mouse variable regions. The Journal of Immunology, 143(11), 3589-3597.